Financials in USD. Standardized financial statements.
A compact view of how COSMOS Pharmaceutical Corporation turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $1.01T | $964.99B | $827.70B | $755.41B | $726.42B | $684.40B | $611.14B | $558.00B | $502.73B | $447.27B |
| Revenue Growth? | +4.8% | +16.6% | +9.6% | +4.0% | +6.1% | +12.0% | +9.5% | +11.0% | +12.4% | 0.0% |
| Cost of Revenue? | $798.11B | $776.68B | $658.98B | $603.97B | $581.31B | $549.42B | $489.35B | $447.68B | $402.69B | $360.42B |
| Gross Profit? | $213.28B | $188.31B | $168.72B | $151.45B | $145.11B | $134.98B | $121.78B | $110.32B | $100.04B | $86.85B |
| Gross Margin? | +21.1% | +19.5% | +20.4% | +20.0% | +20.0% | +19.7% | +19.9% | +19.8% | +19.9% | +19.4% |
| Operating Expenses? | $172.88B | $156.81B | $138.59B | $121.65B | $111.96B | $105.89B | $97.01B | $87.57B | $77.81B | $68.20B |
| Operating Income? | $40.40B | $31.50B | $30.13B | $29.80B | $33.15B | $29.09B | $24.77B | $22.75B | $22.24B | $18.65B |
| EBITDA? | $64.86B | $53.74B | $50.19B | $48.21B | $52.44B | $44.03B | $40.17B | $34.63B | $32.95B | $28.24B |
| Income Before Tax | $42.37B | $33.72B | $32.77B | $33.05B | $38.60B | $30.40B | $27.14B | $25.17B | $25.74B | $20.50B |
| Income Tax Expense | $11.39B | $9.27B | $8.97B | $9.89B | $11.44B | $8.97B | $7.95B | $7.53B | $7.52B | $8.06B |
| Net Income? | $30.98B | $24.45B | $23.80B | $23.16B | $27.16B | $21.43B | $19.18B | $17.63B | $18.21B | $12.44B |
| EPS? | $390.86 | $308.61 | $600.95 | $584.74 | $685.77 | $541.30 | $484.48 | $445.29 | $459.98 | $314.02 |
| Diluted EPS? | $390.86 | $308.61 | $600.95 | $584.74 | $685.77 | $541.30 | $484.48 | $445.29 | $459.98 | $314.02 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality